학술논문

9007 ORAL Phase II Study of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker, in Patients With EGFR FISH-positive Advanced NSCLC
Document Type
Abstract
Source
European Journal of Cancer. Sep2011 Supplement 1, Vol. 47, pS593-S594. 0p.
Subject
Language
ISSN
0959-8049